A team of University of Kentucky Markey Cancer Center researchers has found the mechanism that grants prostate cancer ...

The study looked at two proteins, PLK1 and AURKB, which are often overexpressed in TNBC, an aggressive type of breast cancer. These proteins help regulate how fast cancer cells grow and divide by ...

SAN DIEGO, April 15, 2025 (GLOBE NEWSWIRE) -- Cardiff Oncology, Inc. (Nasdaq: CRDF), a clinical-stage biotechnology company leveraging PLK1 inhibition to develop novel therapies across a range of ...

More information: Monica Gobran et al, PLK1 inhibition delays mitotic entry revealing changes to the phosphoproteome of mammalian cells early in division, The EMBO Journal (2025). DOI: 10.1038 ...

SAN DIEGO, April 15, 2025 (GLOBE NEWSWIRE) -- Cardiff Oncology, Inc. (Nasdaq: CRDF), a clinical-stage biotechnology company leveraging PLK1 inhibition to develop novel therapies across a range of ...

A team of University of Kentucky Markey Cancer Center researchers have found the mechanism that grants prostate cancer resistance to enzalutamide, a frequently used drug treatment.

Here, the authors identify PLK1 inhibition as synthetic lethal with dual BRAF and EGFR inhibition due to loss of ferroptosis inhibition via a PLK1-CBX8-GPX4 signaling axis in preclinical models of ...